Lonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer. A randomized phase II study

ABSTRACT: Primary objective: • Progression-free survival (PFS) Primary end-point: • Progression-free survival (PFS)

DISEASE(S): Metastatisk, Ikke-resektabel Og Kemo-refraktær Kolorektal-kræft,Metastatic, Non-resectable And Chemo-refractory Colorectal Cancer,Colorectal Cancer Metastatic

PROVIDER: 2536542 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR